$104.53
-0.96 (-0.91%)
Performance
1D
—
1W
—
1M
—
3M
—
6M
+32.28%
1Y
+155.88%
YTD
+43.66%
Open$105.00
Previous Close$105.48
Day High$107.04
Day Low$103.37
52W High$130.05
52W Low$36.65
Volume—
Avg Volume549.0K
Market Cap8.51B
P/E Ratio—
EPS$-3.57
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$78.66
Above
SMA 200
$56.03
Above
RSI (14)
77.3
Overbought
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
29 analysts
Price Target
-70.3% upside
Current
$104.53
$104.53
Target
$31.03
$31.03
$20.33
$31.03 avg
$33.62
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 38.18M | 40.50M | 7.83B |
| Net Income | -303,119,226 | -289,450,719 | 335.40M |
| Profit Margin | -794.0% | -754.3% | 4.3% |
| EBITDA | -332,073,898 | -334,716,395 | 592.59M |
| Free Cash Flow | — | — | 369.62M |
| Rev Growth | -5.8% | -5.8% | +18.7% |
| Debt/Equity | 0.00 | 0.00 | 0.53 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $244.33 | -0.76% | 122.9 | 446.67B |
| AMGN | Amgen Inc | $403.48 | -1.07% | 26.5 | 206.48B |
| GILD | Gilead Sciences Inc | $129.97 | -1.36% | 17.6 | 161.72B |
| VRTX | Vertex Pharmaceuticals Inc | $484.53 | -0.06% | 27.8 | 120.52B |
| REGN | Regeneron Pharmaceuticals | $767.54 | -0.14% | 17.5 | 77.36B |
| ALNY | Alnylam Pharmaceuticals Inc | $217.83 | -4.76% | 47.7 | 27.52B |